Patent application number | Description | Published |
20120115909 | TAZAROTENE DERIVATIVES - The presently described subject matter relates to new derivatives of tazarotene that also exhibit retinoid activity, pharmaceutical compositions comprising the derivatives, method of treating skin disorders with the pharmaceutical compositions, and process of making the derivatives. | 05-10-2012 |
20140357669 | TAZAROTENE DERIVATIVES - The presently described subject matter relates to new derivatives of tazarotene that also exhibit retinoid activity, pharmaceutical compositions comprising the derivatives, method of treating skin disorders with the pharmaceutical compositions, and process of making the derivatives. | 12-04-2014 |
20140357672 | TAZAROTENE DERIVATIVES - The presently described subject matter relates to new derivatives of tazarotene that also exhibit retinoid activity, pharmaceutical compositions comprising the derivatives, method of treating skin disorders with the pharmaceutical compositions, and process of making the derivatives. | 12-04-2014 |
Patent application number | Description | Published |
20090030493 | Ribbon Electrode - We disclose an electrode assembly comprising a ribbon electrode having a first surface and a second surface; a plurality of bosses disposed on the second surface of the ribbon electrode, wherein each boss has a third surface substantially not in contact with the second surface of the ribbon electrode and at least one boss is electrically conducting; and an insulator contacting substantially the entire second surface of the ribbon electrode and substantially the entire third surface of each boss; wherein the insulator is substantially not in contact with the first surface of the ribbon electrode. We also disclose an implantable medical device system comprising an implantable medical device for generating an electrical signal; an electrode assembly as described; and a lead wire electrically coupled to both the implantable medical device and at least one electrically conducting boss of the electrode assembly. | 01-29-2009 |
20100106217 | DYNAMIC CRANIAL NERVE STIMULATION BASED ON BRAIN STATE DETERMINATION FROM CARDIAC DATA - A method of treating a medical condition in a patient using an implantable medical device, comprising providing an electrical signal generator; providing at least a first electrode operatively coupled to the electrical signal generator and to a vagus nerve of the patient; sensing cardiac data of the patient; determining at least a first cardiac parameter based upon said cardiac data; setting at least a first value; declaring an unstable brain state of a patient from said at least a first cardiac parameter and said at least a first value; and adjusting the at least a first value. Also, a computer readable program storage device encoded with instructions that, when executed by a computer, performs the method. In addition, the implantable medical device used in the method. | 04-29-2010 |
20110270359 | DELIVERING SCHEDULED AND UNSCHEDULED THERAPY WITHOUT DETRIMENT TO BATTERY LIFE OR ACCURACY OF LONGEVITY PREDICTIONS - A method comprises applying a first open-loop electrical signal to a neural structure at a first rate. The method also comprises applying a closed-loop electrical signal to the neural structure in response to an event detection, thus causing an overall rate at which electrical stimulation is applied to the neural structure to exceed the first rate. The method further comprises applying a second open-loop electrical signal to a neural structure at a second rate that is lower than the first rate, thus causing the overall rate to be reduced to the first rate. | 11-03-2011 |
20120265266 | DEVICE LONGEVITY PREDICTION FOR A DEVICE HAVING VARIABLE ENERGY CONSUMPTION - A system and method for estimating the longevity of an implantable medical device (IMD). In one embodiment of a method for estimating a life of a power source of an implantable medical device, a first life estimate of the power source is determined based on a first open-loop value corresponding to an open-loop parameter for open-loop therapy delivery, a first closed loop value corresponding to a closed-loop parameter for closed-loop therapy delivery, and prior usage data corresponding to prior therapy delivery. The first life estimate of the power source is displayed. The first life estimate displayed includes a first open-loop portion associated with open-loop therapy delivery and a first closed-loop portion associated with closed-loop therapy delivery. | 10-18-2012 |
20120277605 | DYNAMIC HEART RATE THRESHOLD FOR NEUROLOGICAL EVENT DETECTION - A method may include sensing a time of beat sequence of a patient's heart and processing said time of beat sequence with a medical device to identify a change in heart rate of a patient from a first heart rate to a second heart rate. The method may continue by determining with the medical device at least one of a) a ratio of the second heart rate to the first heart rate and b) a difference between the second heart rate and the first heart rate. The method may include determining with the medical device at least one of a) a dynamic ratio threshold for the ratio and b) a dynamic difference threshold for the difference, wherein the at least one threshold is based upon the first heart rate. The ratio and/or the difference may be compared to the threshold(s) to detect a neurological event, for example, an epileptic seizure. | 11-01-2012 |
20130204144 | DYNAMIC CRANIAL NERVE STIMULATION BASED ON BRAIN STATE DETERMINATION FROM CARDIAC DATA - A method of treating a medical condition in a patient using an implantable medical device, comprising providing an electrical signal generator; providing at least a first electrode operatively coupled to the electrical signal generator and to a vagus nerve of the patient; sensing cardiac data of the patient; determining at least a first cardiac parameter based upon said cardiac data; setting at least a first value; declaring an unstable brain state of a patient from said at least a first cardiac parameter and said at least a first value; and adjusting the at least a first value. Also, a computer readable program storage device encoded with instructions that, when executed by a computer, performs the method. In addition, the implantable medical device used in the method. | 08-08-2013 |
20130245464 | DYNAMIC CRANIAL NERVE STIMULATION BASED ON BRAIN STATE DETERMINATION FROM CARDIAC DATA - A method of treating a medical condition in a patient using an implantable medical device, comprising providing an electrical signal generator; providing at least a first electrode operatively coupled to the electrical signal generator and to a vagus nerve of the patient; sensing cardiac data of the patient; determining at least a first cardiac parameter based upon said cardiac data; setting at least a first value; declaring an unstable brain state of a patient from said at least a first cardiac parameter and said at least a first value; and adjusting the at least a first value. Also, a computer readable program storage device encoded with instructions that, when executed by a computer, performs the method. In addition, the implantable medical device used in the method. | 09-19-2013 |
20140121723 | SEIZURE DETECTION USING COORDINATE DATA - A seizure detection device includes a coordinate data interface configured to receive coordinate data for a human, a memory to store coordinate data for a defined location of the human, and a seizure detector configured to identify a seizure event responsive to the coordinate data. | 05-01-2014 |
20140249602 | DEVICE LONGEVITY PREDICTION FOR A DEVICE HAVING VARIABLE ENERGY CONSUMPTION - A system and method for estimating the longevity of an implantable medical device (IMD). In one embodiment of a method for estimating a life of a power source of an implantable medical device, a first life estimate of the power source is determined based on a first open-loop value corresponding to an open-loop parameter for open-loop therapy delivery, a first closed loop value corresponding to a closed-loop parameter for closed-loop therapy delivery, and prior usage data corresponding to prior therapy delivery. The first life estimate of the power source is displayed. The first life estimate displayed includes a first open-loop portion associated with open-loop therapy delivery and a first closed-loop portion associated with closed-loop therapy delivery. | 09-04-2014 |
Patent application number | Description | Published |
20080275211 | METHOD OF MAKING HALOPHTHALIC ACIDS AND HALOPHTHALIC ANHYDRIDES - A method of preparing a halophthalic acid is disclosed which comprises the steps of contacting in a liquid phase reaction mixture at least one halogen-substituted ortho-xylene with oxygen and acetic acid at a temperature in a range between about 120° C. and about 220° C. in the presence of a catalyst system yielding a product mixture comprising less than 10 percent halogen-substituted ortho-xylene starting material, a halophthalic acid product, and less than about 10,000 ppm halobenzoic acid and less than about 1000 ppm halophthalide by-products based on a total amount of halophthalic acid present in the product mixture. In addition methods for the preparation of halophthalic anhydride, and recovery of high purity acetic acid from an aqueous acetic acid stream comprising HCl, which is generated during the preparation of the halophthalic acid are also disclosed. | 11-06-2008 |
20090087383 | NANOPARTICLE-BASED IMAGING AGENTS FOR X-RAY/COMPUTED TOMOGRAPHY AND METHODS FOR MAKING SAME - The present invention is generally directed to core/shell nanoparticles, wherein such core/shell nanoparticles comprise a nanoparticle core and a nanoshell disposed about the nanoparticle core such that, in the aggregate, they form a core/shell nanoparticle that is operable for use as an imaging agent in X-ray/computed tomography (CT). Typically, such core/shell nanoparticle-based X-ray CT imaging agents further comprise a targeting species for targeting the imaging agent to diseased sites. Included herein are methods for forming such agents, comprising forming an ensemble of core/shell nanoparticles, wherein the mean diameter of the ensemble of core/shell nanoparticles is selected so as to render the nanoparticles in the ensemble substantially clearable by a mammalian kidney. | 04-02-2009 |
20100166664 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING - Compositions of nanoparticles functionalized with at least one zwitterionic moiety, methods for making a plurality of nanoparticles, and methods of their use as diagnostic agents are provided. The nanoparticles have characteristics that result in minimal retention of the particles in the body compared to other nanoparticles. The nanoparticle comprises a core, having a core surface essentially free of silica, and a shell attached to the core surface. The shell comprises at least one silane-functionalized zwitterionic moiety. | 07-01-2010 |
20100166665 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING - Compositions of nanoparticles functionalized with at least one zwitterionic moiety, methods for making a plurality of nanoparticles, and methods of their use as diagnostic agents are provided. The nanoparticles have characteristics that result in minimal retention of the particles in the body compared to other nanoparticles. The nanoparticle comprises a core, having a core surface essentially free of silica, and a shell attached to the core surface. The shell comprises at least one silane-functionalized zwitterionic moiety. | 07-01-2010 |
20100166666 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING - Compositions of nanoparticles functionalized with at least one zwitterionic moiety, methods for making a plurality of nanoparticles, and methods of their use as diagnostic agents are provided. The nanoparticles have characteristics that result in minimal retention of the particles in the body compared to other nanoparticles. The nanoparticle comprises a core, having a core surface essentially free of silica, and a shell attached to the core surface. The shell comprises at least one silane-functionalized zwitterionic moiety. | 07-01-2010 |
20100278734 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING - Compositions of nanoparticles functionalized with at least one net positively charged group and at least one net negatively charged group, methods for making a plurality of nanoparticles, and methods of their use as diagnostic agents are provided. The nanoparticles have characteristics that result in minimal retention of the particles in the body compared to other nanoparticles. The nanoparticle comprises a core and a shell. The shell comprises a plurality of silane moieties; at least one silane moiety of the plurality is functionalized with a net positively charged group and at least one silane moiety of the plurality is functionalized with a net negatively charged group. | 11-04-2010 |
20100278748 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING - Compositions of nanoparticles functionalized with at least one net positively charged group and at least one net negatively charged group, methods for making a plurality of nanoparticles, and methods of their use as diagnostic agents are provided. The nanoparticles have characteristics that result in minimal retention of the particles in the body compared to other nanoparticles. The nanoparticle comprises a core and a shell. The shell comprises a plurality of silane moieties; at least one silane moiety of the plurality is functionalized with a net positively charged group and at least one silane moiety of the plurality is functionalized with a net negatively charged group. | 11-04-2010 |
20100278749 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING - Compositions of nanoparticles functionalized with at least one net positively charged group and at least one net negatively charged group, methods for making a plurality of nanoparticles, and methods of their use as diagnostic agents are provided. The nanoparticles have characteristics that result in minimal retention of the particles in the body compared to other nanoparticles. The nanoparticle comprises a core and a shell. The shell comprises a plurality of silane moieties; at least one silane moiety of the plurality is functionalized with a net positively charged group and at least one silane moiety of the plurality is functionalized with a net negatively charged group. | 11-04-2010 |
20110203928 | SILICA REMEDIATION IN WATER - Water treatment methods for reducing silica concentration in water containing at least 100 ppm dissolved or suspended silica include contacting the water with particles comprising mesoporous alumina having surface area ranging from about 250 m2/g to about 600 m | 08-25-2011 |
20120093703 | CATALYST AND METHOD OF MANUFACTURE - A catalyst composition includes a catalytic metal secured to a porous substrate. The substrate has pores that are templated. The catalyst composition is prepared by a process that includes the steps of mixing a catalytic metal salt, a templating agent, and water to form a mixture, adding a substrate precursor to the mixture to form a slurry, and calcining the slurry to form a substrate having a porous template that is capable of supporting the catalyst composition. | 04-19-2012 |
20130128713 | REVERSE SATURABLE ABSORBTION SENSITIZERS FOR OPTICAL DATA STORAGE MEDIA AND METHODS FOR USE - The invention relates generally to optical data storage media, and more specifically, to holographic storage media. In one embodiment, an optical storage medium composition includes a polymer matrix. Disposed within the polymer matrix is a reactant capable of undergoing a modification that alters the refractive index of the composition upon receiving an energy transfer from an excited sensitizer. A non-linear sensitizer is also disposed within the polymer matrix, and the sensitizer includes a metal-substituted subphthalocyanine (M-sub-PC) reverse saturable absorber configured to become excited upon exposure to light beyond an intensity threshold at approximately 405 nm and configured to transfer energy to the reactant. | 05-23-2013 |
20140002220 | NANOCOMPOSITE PERMANENT MAGNETS AND METHODS OF MAKING THE SAME | 01-02-2014 |
20140056819 | NANOPARTICULATE COMPOSITIONS FOR DIAGNOSTIC IMAGING - The present invention provides a trialkoxysilanes having structure I | 02-27-2014 |
20140056821 | NANOPARTICULATE COMPOSITIONS FOR DIAGNOSTIC IMAGING - The present invention provides a trialkoxysilane having structure I | 02-27-2014 |
20140147387 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING - Compositions of nanoparticles functionalized with at least one zwitterionic moiety, methods for making a plurality of nanoparticles, and methods of their use as diagnostic agents are provided. The nanoparticles have characteristics that result in minimal retention of the particles in the body compared to other nanoparticles. The nanoparticle comprising a nanoparticulate transition metal oxide covalently functionalized with a silane-functionalized non-targeting zwitterionic moiety. | 05-29-2014 |
20140252264 | SOFT MAGNETIC PHASE NANOPARTICLES PREPARATIONS AND ASSOCIATED METHODS THEREOF - A method of synthesizing magnetic nanoparticles comprising soft magnetic phases is provided, wherein the method comprises degassing a first mixture at a temperature in a range from about 80° C. to 130° C. The first mixture comprises a solvent, a compound comprising iron, cobalt, or combinations thereof dissolved in the solvent, and an organic component comprising a fatty acid or an amine. Degassing the first mixture is followed by adding a capping ligand to the first mixture under inert atmosphere to form a second mixture; adding a reducing agent to the second mixture at a temperature in a processing temperature range from about 250° C. to about 350° C. to form a third mixture; and incubating the third mixture at a temperature within the processing temperature range to form nanoparticles comprising a soft magnetic phase. | 09-11-2014 |